Literature DB >> 20352017

Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Lilian Varricchio1, Annalisa Mancini, Anna Rita Migliaccio.   

Abstract

Primary myelofibrosis (PMF) belongs to the Philadelphia-negative myeloproliferative neoplasms and is a hematological disorder caused by abnormal function of the hematopoietic stem cells. The disease manifests itself with a plethora of alterations, including anemia, splenomegaly and extramedullary hematopoiesis. Its hallmarks are progressive marrow fibrosis and atypical megakaryocytic hyperplasia, two distinctive features used to clinically monitor disease progression. In an attempt to investigate the role of abnormal megakaryocytopoiesis in the pathogenesis of PMF, several transgenic mouse models have been generated. These models are based either on mutations that interfere with the extrinsic (thrombopoietin and its receptor, MPL) and intrinsic (the GATA1 transcription factor) control of normal megakaryocytopoiesis, or on known genetic lesions associated with the human disease. Here we provide an up-to-date review on the insights into the pathobiology of human PMF achieved by studying these animal models, with particular emphasis on results obtained with Gata1(low) mice.

Entities:  

Year:  2009        PMID: 20352017      PMCID: PMC2845468          DOI: 10.1586/ehm.09.17

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  197 in total

1.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

2.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

3.  The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.

Authors:  D W Sternberg; M H Tomasson; M Carroll; D P Curley; G Barker; M Caprio; A Wilbanks; A Kazlauskas; D G Gilliland
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

4.  The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.

Authors:  Louis M Pelus; Huimin Bian; Seiji Fukuda; Donald Wong; Ahmed Merzouk; Hassan Salari
Journal:  Exp Hematol       Date:  2005-03       Impact factor: 3.084

5.  Isolation of TPO-dependent subclones from the multipotent 32D cell line.

Authors:  Giovanni Amabile; Antonella Di Noia; Elena Alfani; Alessandro Maria Vannucchi; Massimo Sanchez; Domenico Bosco; Anna Rita Migliaccio; Giovanni Migliaccio
Journal:  Blood Cells Mol Dis       Date:  2005 Sep-Oct       Impact factor: 3.039

6.  The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.

Authors:  Vittorio Rosti; Margherita Massa; Alessandro M Vannucchi; Gaetano Bergamaschi; Rita Campanelli; Alessandro Pecci; Gianluca Viarengo; Valentina Meli; Monia Marchetti; Paola Guglielmelli; Edward Bruno; Mingjiang Xu; Ronald Hoffman; Giovanni Barosi
Journal:  Blood Cells Mol Dis       Date:  2007-03-09       Impact factor: 3.039

7.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Authors:  B J Longley; L Tyrrell; S Z Lu; Y S Ma; K Langley; T G Ding; T Duffy; P Jacobs; L H Tang; I Modlin
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Authors:  Shu Xing; Tina Ho Wanting; Wanming Zhao; Junfeng Ma; Shaofeng Wang; Xuesong Xu; Qingshan Li; Xueqi Fu; Mingjiang Xu; Zhizhuang Joe Zhao
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

9.  Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Wei Tong
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

Review 10.  Primary myelofibrosis: update on definition, pathogenesis, and treatment.

Authors:  Omar I Abdel-Wahab; Ross L Levine
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

View more
  15 in total

1.  CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Authors:  Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

3.  Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Authors:  Ann Mullally; Luke Poveromo; Rebekka K Schneider; Fatima Al-Shahrour; Steven W Lane; Benjamin L Ebert
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

4.  Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.

Authors:  Koen Schepers; Eric M Pietras; Damien Reynaud; Johanna Flach; Mikhail Binnewies; Trit Garg; Amy J Wagers; Edward C Hsiao; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2013-07-11       Impact factor: 24.633

Review 5.  Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.

Authors:  Nikolaos Papadantonakis; Shinobu Matsuura; Katya Ravid
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

6.  Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells.

Authors:  Gergely T Kozma; Fabrizio Martelli; Maria Verrucci; Laura Gutiérrez; Giovanni Migliaccio; Massimo Sanchez; Elena Alfani; Sjaak Philipsen; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

7.  Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.

Authors:  Edwin Chen; Rebekka K Schneider; Lawrence J Breyfogle; Emily A Rosen; Luke Poveromo; Shannon Elf; Amy Ko; Kristina Brumme; Ross Levine; Benjamin L Ebert; Ann Mullally
Journal:  Blood       Date:  2014-10-03       Impact factor: 22.113

8.  Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.

Authors:  Maria Zingariello; Fabrizio Martelli; Fiorella Ciaffoni; Francesca Masiello; Barbara Ghinassi; Emanuela D'Amore; Margherita Massa; Giovanni Barosi; Laura Sancillo; Xiaochun Li; Judith D Goldberg; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Blood       Date:  2013-03-05       Impact factor: 22.113

9.  Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice.

Authors:  Koen Schepers; Edward C Hsiao; Trit Garg; Mark J Scott; Emmanuelle Passegué
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function.

Authors:  Alexandra Mazharian; Ying-Jie Wang; Jun Mori; Danai Bem; Brenda Finney; Silke Heising; Paul Gissen; James G White; Michael C Berndt; Elizabeth E Gardiner; Bernhard Nieswandt; Michael R Douglas; Robert D Campbell; Steve P Watson; Yotis A Senis
Journal:  Sci Signal       Date:  2012-10-30       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.